After weight loss and arthritis, the popular diabetic drug Ozempic (semaglutide) has now been linked to curing alcoholism. A research published in JAMA Psychiatry found that patients diagnosed with Alcohol Use Disorder (AUD), who were given a GLP-1 drug were less likely to be hospitalized for alcohol-related issues. Moreover, they found it to work even better than the current most effective drug for treating alcoholism on the market. About 12.5% of India's population suffers from AUD, according to the latest reports. Researchers Analysed Over 2 Lakh PatientsFor the study, researchers analysed medical records of 228,000 people diagnosed with ADD between 2006 and 2023. All of these patients had Obesity or Type 2 Diabetes. During the course of the research, 60% per cent of the population was hospitalised. However, alcohol-related hospitalizations were dramatically lower among people who took a GLP-1 drug.Notably, GLP-1 drugs include semaglutide, which is sold under the brand names Ozempic and Wegovy. The study found that it reduced the hospitalization risk by 22% in alcoholic patients. Another GLP-1 drug, liraglutide, which is sold under the brand name Victoza, lowered the hospitalization risk by 21%. Are Their Any Side Effects Of Semaglutide?Semaglutide, marketed under the brand name Ozempic, is primarily an antidiabetic medication used to treat Type 2 diabetes. It is also an anti-obesity drug used for long-term weight management. While it can be taken as a subcutaneous injection or orally, it has significant side effects. It primarily impacts your gastrointestinal tract and its side effects include constipation, nausea, abdominal pain, diarrhoea, and fatigue amongst others.Semaglutide Can Reduce Knee PainThis comes as research found that semaglutide injections can reduce knee pain caused by obesity-related arthritis. This could, in turn, make everyday activities like walking easier for arthritis patients. Semaglutide is a GLP-1 receptor agonist, a class of drugs that helps regulate blood sugar, control appetite, and promote weight loss. Ozempic is one of the forms of this drug.Approximately 400 participants from 11 countries were given either weekly semaglutide injections or a placebo, along with advice on healthy eating and exercise. Initially, participants reported an average pain score of 71 out of 100, reflecting considerable discomfort when walking. After 68 weeks, those who received semaglutide experienced an average pain reduction of 42 points, significantly higher than the 28-point decrease observed in the placebo group.